SOURCE: PetLife Pharmaceuticals, Inc.

August 11, 2014 16:15 ET

PetLife to Begin Trading on OTCQB; Company Closes Acquisition, Reverse Split, Name and Ticker Change

BEVERLY HILLS, CA--(Marketwired - Aug 11, 2014) - PetLife Pharmaceuticals, Inc. (formerly Clear TV Ventures, Inc. and formerly Eco Ventures Group, Inc.) (PINKSHEETS: EVGI), today announced it will begin trading as a public company on the OTCQB tomorrow, Tuesday, August 12, at the market open under the ticker symbol EVGID.

Its common stock will also reflect a one-for-twenty reverse exchange as one of the conditions of closing its acquisition. The current ticker will have a D appended to it, as EVGID, for the first 20 business days as FINRA regulations require, following which the new symbol will be PTLF. (No action is or will be required by current shareholders, whose shareholdings will be automatically adjusted by broker-dealers and/or at the transfer agent.) In conjunction with the changes, PetLife's common stock will have a new CUSIP number: 71639B 105 beginning August 12.

The Company has closed its acquisition, through a share exchange agreement, with Beverly Hills, CA-based PetLife Corporation. Its pending new ticker symbol, and recent name change, have been filed with and accepted by FINRA.

According to the terms of the Agreement, PetLife's shareholders received 47 million shares of EVGI common stock, which equates to approximately 80 percent of the issued and outstanding shares of EVGI in consideration for 100 percent of PetLife capital stock. Post-Closing and share rollback, the Company will have approximately 58 million shares issued and outstanding. Details on the transaction are contained in PetLife's report being filed this week on Form 8-K with the SEC.

PetLife is preparing to launch its new website in mid-August.

About Petlife Corporation
PetLife is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and is a spinoff of Medolife Corp.

PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries -- using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.

Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: EVGI encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at Statements released by Eco Ventures Group, Inc. that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.